Heron Therapeutics, INC /DE/ Form 4 insider transactions

Heron Therapeutics' EVP, Chief Development Officer, William P. Forbes, converted 11,695 restricted stock units into common stock.

Heron Therapeutics CEO Craig Collard converted 34,789 restricted stock units into common stock, increasing his direct ownership.

Heron Therapeutics' EVP, Chief Development Officer, William P. Forbes, converted 3,875 restricted stock units into common stock.

Heron Therapeutics' EVP and CFO, Ira Duarte, acquired 3,875 shares of common stock through the vesting of restricted stock units.

Heron Therapeutics CEO Craig Collard acquired 13,797 shares of common stock through the exercise of restricted stock units.

Heron Therapeutics Director Thomas Cusack received grants of restricted stock units and stock options, vesting over several years.

Heron Therapeutics' EVP, Chief Development Officer, William P. Forbes, converted 11,694 restricted stock units into common stock.

Heron Therapeutics' EVP and CFO, Ira Duarte, acquired 11,694 shares of common stock through the vesting of restricted stock units.

Heron Therapeutics CEO Craig Collard converted 34,789 restricted stock units into common stock, increasing his direct beneficial ownership.

Heron Therapeutics' EVP, William P. Forbes, converted 3,874 restricted stock units into common stock, increasing his direct beneficial ownership.

Heron Therapeutics' EVP and CFO, Ira Duarte, acquired 3,874 shares of common stock through the scheduled vesting of restricted stock units on October 19, 2025.

Heron Therapeutics CEO Craig Collard acquired 13,797 shares of common stock through the vesting of restricted stock units, increasing his direct beneficial ownership.

Rubric Capital Management LP and David Rosen reported the conversion of Series A Convertible Preferred Stock into 946,100 shares of Heron Therapeutics common stock, increasing their indirect common stock holdings to over 30 million shares.

Rubric Capital Management LP and David Rosen significantly increased their beneficial ownership in Heron Therapeutics, Inc. through purchases of common stock, convertible notes, and preferred shares.

A director of Heron Therapeutics, Inc. acquired approximately $3.8 million in common and convertible preferred stock through a private placement, increasing beneficial ownership.

Heron Therapeutics' EVP, Chief Development Officer, William P. Forbes, converted 11,695 restricted stock units into common stock.

Heron Therapeutics CFO Ira Duarte converted 11,695 restricted stock units into common stock, correcting prior filing errors.

Heron Therapeutics CEO Craig Collard acquired 34,789 common shares through the vesting of restricted stock units.

Heron Therapeutics' EVP and Chief Development Officer, William P. Forbes, acquired 3,874 shares of common stock through the vesting and conversion of restricted stock units.

Heron Therapeutics' EVP and Chief Financial Officer, Ira Duarte, converted 3,874 restricted stock units into common shares, increasing direct beneficial ownership of common stock.

Heron Therapeutics CEO Craig A. Collard acquired 13,797 shares of common stock through the conversion of restricted stock units, increasing his direct beneficial ownership.

Heron Therapeutics, Inc.'s Executive Vice President and Chief Financial Officer, Ira Duarte, acquired 12,500 shares of common stock on June 16, 2025, through the vesting and conversion of restricted stock units.

William P. Forbes, EVP and Chief Development Officer of Heron Therapeutics, acquired 12,500 shares of common stock through the vesting of restricted stock units.

Mark Earl Hensley, Chief Operating Officer of Heron Therapeutics, received 500,000 restricted stock units on May 6, 2025, according to a Form 4 filing.

William P. Forbes, EVP and Chief Development Officer of Heron Therapeutics, exercised stock options and acquired 11,694 shares of common stock on April 30, 2025.

Ira Duarte, EVP and CFO of Heron Therapeutics, reports the vesting of restricted stock units and subsequent acquisition of common stock.

Craig Collard, CEO of Heron Therapeutics, reports the disposition of 34,789 shares of common stock on April 30, 2025, through the vesting of restricted stock units.

Mark Earl Hensley, Chief Operating Officer of Heron Therapeutics, received employee stock options on April 28, 2025.

William P. Forbes, EVP and Chief Development Officer of Heron Therapeutics, reports a transaction involving the exercise of stock options.

Ira Duarte, EVP and CFO of Heron Therapeutics, reports the vesting of 3,875 common stock units on April 19, 2025, according to a Form 4 filing.